DexCom reported third-quarter 2026 revenue of $1.344 billion, an 11% increase year-over-year, driven by a 14% rise in U.S. sales. GAAP operating income reached $327.2 million (24.3% margin), while non-GAAP diluted EPS was $0.73. The company raised its full-year revenue guidance to $5.20-$5.25 billion and increased margins for non-GAAP operating profit and adjusted EBITDA. Concurrently, the Board authorized a new share repurchase program of up to $1.0 billion, valid through December 31, 2027. DexCom develops continuous glucose monitoring systems for diabetes management.
